Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia
Authors:
- 7 October 2011
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 26 (4) , 841-844
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical featuresLeukemia Research, 2009
- Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic LeukemiaCancer Research, 2008
- Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of CancerCancer Research, 2007
- APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survivalHaematologica, 2007
- BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathwayBlood, 2006
- Search on Chromosome 17 Centromere Reveals TNFRSF13B as a Susceptibility Gene for Intracranial AneurysmCirculation, 2006
- Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative DisordersJournal of Clinical Oncology, 2006
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentBlood, 1996